Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Altuviiio™ (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl) – New orphan drug approval
February 22, 2023 - The FDA approved Bioverativ Therapeutics and Sanofi’s Altuviiio (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl).
